GSK 1437173A

Drug Profile

GSK 1437173A

Alternative Names: GSK1437173A; Herpes zoster vaccine candidate (Hz/su) - GlaxoSmithKline; QS-21 containing herpes zoster vaccine - GlaxoSmithKline/Agenus; recombinant adjuvanted Herpes Zoster vaccine - GlaxoSmithKline; Shingrix; Varicella zoster vaccine - GlaxoSmithKline; Varicella zoster virus vaccine - GlaxoSmithKline; VZV gE; VZV vaccine - GlaxoSmithKline/Agenus

Latest Information Update: 10 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Japan Vaccine
  • Class Subunit vaccines; Varicella vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Herpes zoster

Most Recent Events

  • 02 Jul 2018 Registered for Herpes zoster (Prevention, In adults, In the elderly) in Australia (IM) (TGA website, August 2018)
  • 18 Jun 2018 The National Advisory Committee on Immunization (NACI) strongly recommends GSK 1437173A for Herpes zoster (In adults) (Prevention)
  • 23 Apr 2018 Committee on Immunization of Quebec recommends preferential use of GSK 1437173A for Herpes zoster (Prevention)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top